Gujarat Kidney and Super Speciality Ltd has issued a corrigendum to its FY26 Annual Report to include omitted Secretarial Audit observations and management responses. The company said the omission was inadvertent and does not affect its financial performance or the 7th AGM. The filing also highlights strong FY26 revenue and profit growth, along with shareholder proposals on higher borrowing limits, director appointments and revised managerial remuneration.
Gujarat Kidney and Super Speciality Issues Annual Report Corrigendum Ahead of AGM
FY26 Consolidated Revenue: Rs 82.01 crore
FY26 Consolidated PAT: Rs 16.80 crore
Reader Takeaway: Strong financial growth offsets governance disclosures, but investors should monitor execution of governance improvements.
What just happened
Gujarat Kidney and Super Speciality Ltd has issued a corrigendum to its FY2025-26 Annual Report to incorporate observations from the Secretarial Audit Report along with management's responses that were inadvertently omitted from the original document.
The company clarified that the omission does not affect its financial performance, financial statements or any resolutions proposed for its 7th Annual General Meeting scheduled on September 28, 2026.
Why this matters
The corrigendum improves disclosure by including governance-related observations before shareholders vote at the AGM.
The filing also outlines several important resolutions, including higher borrowing powers, enhanced investment limits, revision in managerial remuneration, appointments of independent directors and the appointment of a secretarial auditor.
Financial performance
The company reported strong growth during FY2025-26.
On a consolidated basis:
- Revenue increased to Rs 82.01 crore from Rs 40.24 crore.
- Profit after tax rose to Rs 16.80 crore from Rs 9.50 crore.
On a standalone basis:
- Revenue increased to Rs 40.10 crore from Rs 35.17 crore.
- Profit after tax improved to Rs 9.90 crore from Rs 9.11 crore.
What changes now
Shareholders will consider several special resolutions at the AGM, including:
- Increasing the Board's borrowing limit to Rs 500 crore.
- Raising the ceiling for loans, guarantees and investments under Section 186 to Rs 500 crore.
- Approval of revised remuneration for the Managing Director and Whole-time Director.
- Appointment of two Independent Directors for five-year terms.
- Appointment of SPANJ & Associates as Secretarial Auditor for five years.
Risks to watch
The Secretarial Audit highlighted certain compliance observations.
The company acknowledged that it did not fully spend the required CSR amount during FY26 but stated that the unspent amount was transferred to the PM CARES Fund within the prescribed statutory timeline.
Management also acknowledged delays in submitting financial results for the quarter ended September 30, 2025, and failure to provide prior intimation of a Board meeting during that period. The company stated these lapses were unintentional and that internal monitoring mechanisms have since been strengthened.
The backstory
Following its IPO completed in December 2025, Gujarat Kidney and Super Speciality is deploying capital towards a new hospital in Vadodara while also pursuing inorganic expansion through acquisitions, including Harmony Medicare and Parekhs Hospital. Management continues to focus on expanding healthcare capacity while improving operational efficiency.
What to track next
Investors should monitor the AGM outcome, progress of the Vadodara hospital project, integration of acquired healthcare assets, utilization of enhanced borrowing capacity if approved, and improvements in compliance processes following the governance observations.